Meeting
2014 ASCO Annual Meeting
Plasma levels and tumor tissue RNA of MMP2 and MMP9 exhibit similar distribution in newly diagnosed and recurrent glioblastoma (GB).
Authors
Emeline Tabouret
Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France
Emeline Tabouret , Francoise Boudouresque , Emilie Denicolai , Maryline Barrie , Celine Boucard , Philippe Metellus , Didier Autran , Alexia Terciolo , Dominique Figarella-Branger , L'houcine Ouafik , Olivier L. Chinot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2074)
DOI
10.1200/jco.2014.32.15_suppl.2074
Abstract #
2074
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.
First Author: Olivier L. Chinot
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2020 ASCO Virtual Scientific Program
Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study.
First Author: Shin-Ichi Miyatake